My lab’s vision for the next five years is to apply what we have learned to develop molecules that can alter FA protein behavior. These could be used to treat cancer or alter gene editing outcomes.
Directory
![](https://fanconi.org/wp-content/uploads/2018/04/shimamura_akiko_1-271-1531417081.jpg)
Akiko Shimamura
Bone Marrow Failure and Myelodysplastic Syndrome Program | MD, PhD | Boston, USA
Dr. Shimamura directs the Bone Marrow Failure and Myelodysplastic Syndrome Program of the Dana Farber/Boston Children’s Cancer and Blood Disorders Center. Her research focuses on translational studies spanning clinical through basic science investigations to understand the genetic and molecular basis of bone marrow failure, MDS, and leukemia predisposition with the goal of developing more effective and less toxic treatments. Dr. Shimamura had previously directed the Bone Marrow Failure Clinic at Boston Children’s Hospital and then at Seattle Children’s Hospital before returning to Boston Children’s Hospital in the fall of 2015.
Dr. Shimamura has mentored numerous students and post-doctoral fellows who have moved on to careers in academics, medicine, or the biotechnology industry.
FA Research Projects
The Latest
News & Events
![](https://fanconi.org/wp-content/uploads/2024/06/IMG_1499s-scaled-e1718991245321-1024x554.jpg)
![](https://fanconi.org/wp-content/uploads/2024/06/Omar7-778x1024.png)
In a world where every day presents new challenges, my 11-year-old son, Omar, from Oman, stands out for his resilience and eagerness to raise awareness about Fanconi anemia. Diagnosed at just five years old, we truly believe his journey is a testament to hope and the strength of the human spirit.
![](https://fanconi.org/wp-content/uploads/2024/04/Copy-of-FCF-Social-Media-Templates-1024x1024.png)
That's why we're thrilled to announce the launch of the Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research, a flagship funding opportunity in partnership with the American Association for Cancer Research (AACR).